Fig. 2From: Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective studyKaplan-Meier curves showing (a) progression-free survival and (b) overall survival. CI: confidence interval; HR: hazard ratioBack to article page